Geoffrey A. Swire
Chief Operating Officer at ALLENA PHARMACEUTICALS, INC.
Geoffrey A. Swire active positions
| Companies | Position | Start | End |
|---|---|---|---|
| ALLENA PHARMACEUTICALS, INC. | Chief Operating Officer | 2020-11-09 | - |
| Corporate Officer/Principal | 2017-12-31 | - |
Career history of Geoffrey A. Swire
Former positions of Geoffrey A. Swire
| Companies | Position | Start | End |
|---|---|---|---|
Genzyme Corp.
 Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - | - |
| RADIUS HEALTH, INC. | Corporate Officer/Principal | - | - |
Training of Geoffrey A. Swire
| Dartmouth College | Undergraduate Degree |
| Harvard University | Graduate Degree |
Statistics
International
| United States | 6 |
Operational
| Corporate Officer/Principal | 3 |
| Undergraduate Degree | 1 |
| Chief Operating Officer | 1 |
Sectoral
| Health Technology | 4 |
| Consumer Services | 3 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| ALLENA PHARMACEUTICALS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Radius Health, Inc.
 Radius Health, Inc. BiotechnologyHealth Technology Radius Health, Inc. is a biopharmaceutical company, which engages in developing and commercializing endocrine therapeutics in the areas of osteoporosis and oncology. The company’s lead product, Abaloparatide-SC, reduces fracture risk in postmenopausal women with osteoporosis. Its pipeline also includes the abaloparatide transdermal patch for potential use in osteoporosis, and RAD1901 for potential use in hormone-driven, or hormone-resistant, metastatic breast cancer, and vasomotor symptoms in postmenopausal women. The company was founded by John Katzenellenbogen, Stavros C. Manolagas, Michael Rosenblatt, and John T. Potts on October 3, 2003 and is headquartered in Boston, MA. | Health Technology |
- Stock Market
- Insiders
- Geoffrey A. Swire
- Experience
